Previous Close | 0.4050 |
Open | 0.0000 |
Bid | 0.3700 x N/A |
Ask | 0.4150 x N/A |
Day's Range | 0.4050 - 0.4050 |
52 Week Range | 0.3500 - 6.3800 |
Volume | |
Avg. Volume | 38,003 |
Market Cap | 6.286M |
Beta (5Y Monthly) | 2.45 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -5.0900 |
Earnings Date | May 16, 2019 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Subscribe to Yahoo Finance Plus to view Fair Value for COOL.CN
VANCOUVER, British Columbia, April 06, 2022 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: “COOL”), (OTCQB: “CLABF”), (Frankfurt: LD6, WKN: A3CSSU) (the “Company” or “Core One”) a life sciences biotechnology research and development company focused on bringing psychedelic medicines to market through the development and production of psychedelic compounds, the advancement of psychedelic assisted treatments, and the integration of novel delivery systems technology is pleased to announce that it has
Will Look to Advance its Psychedelic Based FormulationsVANCOUVER, British Columbia, April 02, 2022 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (the “Company” or “Core One”) is pleased to announce that its wholly owned subsidiary Akome Biotech Ltd. (“Akome”) through a research arrangement with Neuro-Zone Srl, (“Neuro-Zone”) based in Bresso, Italy, has achieved positive results from its in vitro biological assay (“bioassay”) development studies (
VANCOUVER, British Columbia, March 19, 2022 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (the “Company” or “Core One”) announces that following its recently announced developments it is actively working to investigate investment and potential takeover opportunities by strategic psychedelics or pharmaceutical companies. “Acquisition or investment by a major pharmaceutical company could be mutually beneficial. As more research comes to light regar